novel coronavirus pneumonia
Conditions
Interventions
B:Lactococcus Lactis
A: antiviral polypeptide LL-37 preparation
Sponsors
Chinese PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: (1) all patients with clearly diagnosed novel coronavirus pneumonia who voluntarily receive treatment and do not participate in other clinical trials; (2) aged >=18 years, approved by the ethics committee, fully understand and sign the informed consent.
Exclusion criteria
Exclusion criteria: (1) those who do not meet the above inclusion criteria; (2) pregnant and lactating women; (3) severe basic diseases of the liver (Child Pugh score >=C, AST > 5 times the upper limit); (4) serious renal damage basic diseases (estimated glomerular filtration rate <=30 ml/min / 1.73 m2, or is undergoing continuous renal replacement therapy, hemodialysis, peritoneal dialysis); (5) people who accepted any novel coronavirus pneumonia experimental treatment within 30days prior to evaluation; (6) people who are allergic to lactococcus lactis or pharmaceutical excipients.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| nuclear acid test of the upper respiratory tract;CT test of lung;nuclear acid test of stool; | — |
Countries
China
Contacts
Public Contactsun gang
Outcome results
None listed